Stately Bio has validated its technology through multiple partnerships across different cell types and use cases. In a recent preclinical study with the New York Blood Center, Stately Bio’s ML platform was able to identify specific subpopulations of stem cell-derived immune cells faster and more efficiently than gold-standard flow cytometry and immunofluorescence assays.
Organizations Involved
New York Blood Center
Founders
Frank Li
Company Description
Stately Bio is the trade-off between measuring cells and keeping them alive.
Market
Regenerative Medicine
Location
Palo Alto,
California,
USA
Coinvestors
AIX Ventures, Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean, Jeremy Wertheimer, Tom Berry